BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 15292940)

  • 21. IDH-mutated astrocytomas with 19q-loss constitute a subgroup that confers better prognosis.
    Otani R; Uzuka T; Higuchi F; Matsuda H; Nomura M; Tanaka S; Mukasa A; Ichimura K; Kim P; Ueki K
    Cancer Sci; 2018 Jul; 109(7):2327-2335. PubMed ID: 29752851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Histological and molecular classification of gliomas].
    Figarella-Branger D; Colin C; Coulibaly B; Quilichini B; Maues De Paula A; Fernandez C; Bouvier C
    Rev Neurol (Paris); 2008; 164(6-7):505-15. PubMed ID: 18565348
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Correlation between loss of heterozygosity on chromosome 1p and 19q and expression of MGMT, p53 and Ki-67 proteins in gliomas].
    Huang L; Jiang T; Yuan F; Li GL; Xu LX; Cui Y
    Zhonghua Zhong Liu Za Zhi; 2011 Oct; 33(10):752-8. PubMed ID: 22335907
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.
    Dubbink HJ; Atmodimedjo PN; Kros JM; French PJ; Sanson M; Idbaih A; Wesseling P; Enting R; Spliet W; Tijssen C; Dinjens WN; Gorlia T; van den Bent MJ
    Neuro Oncol; 2016 Mar; 18(3):388-400. PubMed ID: 26354927
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cystathionine as a marker for 1p/19q codeleted gliomas by in vivo magnetic resonance spectroscopy.
    Branzoli F; Pontoizeau C; Tchara L; Di Stefano AL; Kamoun A; Deelchand DK; Valabrègue R; Lehéricy S; Sanson M; Ottolenghi C; Marjańska M
    Neuro Oncol; 2019 Jun; 21(6):765-774. PubMed ID: 30726924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors.
    Ueki K; Nishikawa R; Nakazato Y; Hirose T; Hirato J; Funada N; Fujimaki T; Hojo S; Kubo O; Ide T; Usui M; Ochiai C; Ito S; Takahashi H; Mukasa A; Asai A; Kirino T
    Clin Cancer Res; 2002 Jan; 8(1):196-201. PubMed ID: 11801559
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas.
    Watanabe T; Nakamura M; Kros JM; Burkhard C; Yonekawa Y; Kleihues P; Ohgaki H
    Acta Neuropathol; 2002 Mar; 103(3):267-75. PubMed ID: 11907807
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low FoxG1 and high Olig-2 labelling indices define a prognostically favourable subset in isocitrate dehydrogenase (IDH)-mutant gliomas.
    Schäfer S; Behling F; Skardelly M; Koch M; Ott I; Paulsen F; Tabatabai G; Schittenhelm J
    Neuropathol Appl Neurobiol; 2018 Feb; 44(2):207-223. PubMed ID: 29053887
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histogram analysis of MR imaging-derived cerebral blood volume maps: combined glioma grading and identification of low-grade oligodendroglial subtypes.
    Emblem KE; Scheie D; Due-Tonnessen P; Nedregaard B; Nome T; Hald JK; Beiske K; Meling TR; Bjornerud A
    AJNR Am J Neuroradiol; 2008 Oct; 29(9):1664-70. PubMed ID: 18583405
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High rate of deletion of chromosomes 1p and 19q in insular oligodendroglial tumors.
    Wu A; Aldape K; Lang FF
    J Neurooncol; 2010 Aug; 99(1):57-64. PubMed ID: 20035368
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic.
    Li YX; Shi Z; Aibaidula A; Chen H; Tang Q; Li KK; Chung NY; Chan DT; Poon WS; Mao Y; Wu J; Zhou L; Chan AK; Ng HK
    Oncotarget; 2016 Oct; 7(40):64615-64630. PubMed ID: 27556304
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pleomorphic xanthoastrocytoma and oligodendroglioma: collision of 2 morphologically and genetically distinct anaplastic components.
    Hattab EM; Martin SE; Shapiro SA; Cheng L
    J Neurosurg; 2011 Jun; 114(6):1648-53. PubMed ID: 21214337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frequent BRAF gain in low-grade diffuse gliomas with 1p/19q loss.
    Kim YH; Nonoguchi N; Paulus W; Brokinkel B; Keyvani K; Sure U; Wrede K; Mariani L; Giangaspero F; Tanaka Y; Nakazato Y; Vital A; Mittelbronn M; Perry A; Ohgaki H
    Brain Pathol; 2012 Nov; 22(6):834-40. PubMed ID: 22568401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors.
    McDonald JM; See SJ; Tremont IW; Colman H; Gilbert MR; Groves M; Burger PC; Louis DN; Giannini C; Fuller G; Passe S; Blair H; Jenkins RB; Yang H; Ledoux A; Aaron J; Tipnis U; Zhang W; Hess K; Aldape K
    Cancer; 2005 Oct; 104(7):1468-77. PubMed ID: 16088966
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype.
    Smith JS; Alderete B; Minn Y; Borell TJ; Perry A; Mohapatra G; Hosek SM; Kimmel D; O'Fallon J; Yates A; Feuerstein BG; Burger PC; Scheithauer BW; Jenkins RB
    Oncogene; 1999 Jul; 18(28):4144-52. PubMed ID: 10435596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation of molecular genetics with molecular and morphological imaging in gliomas with an oligodendroglial component.
    Walker C; du Plessis DG; Fildes D; Haylock B; Husband D; Jenkinson MD; Joyce KA; Broome J; Kopitski K; Prosser J; Smith T; Vinjamuri S; Warnke PC
    Clin Cancer Res; 2004 Nov; 10(21):7182-91. PubMed ID: 15534091
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical utility of fluorescence in situ hybridization (FISH) in morphologically ambiguous gliomas with hybrid oligodendroglial/astrocytic features.
    Fuller CE; Schmidt RE; Roth KA; Burger PC; Scheithauer BW; Banerjee R; Trinkaus K; Lytle R; Perry A
    J Neuropathol Exp Neurol; 2003 Nov; 62(11):1118-28. PubMed ID: 14656070
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship between radiological characteristics and combined 1p and 19q deletion in World Health Organization grade III oligodendroglial tumours.
    Kim JW; Park CK; Park SH; Kim YH; Han JH; Kim CY; Sohn CH; Chang KH; Jung HW
    J Neurol Neurosurg Psychiatry; 2011 Feb; 82(2):224-7. PubMed ID: 20587495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The 2016 revision of the WHO Classification of Central Nervous System Tumours: retrospective application to a cohort of diffuse gliomas.
    Rogers TW; Toor G; Drummond K; Love C; Field K; Asher R; Tsui A; Buckland M; Gonzales M
    J Neurooncol; 2018 Mar; 137(1):181-189. PubMed ID: 29218432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic variables in oligodendroglial tumors: a single-institution study of 95 cases.
    Scheie D; Meling TR; Cvancarova M; Skullerud K; Mørk S; Lote K; Eide TJ; Helseth E; Beiske K
    Neuro Oncol; 2011 Nov; 13(11):1225-33. PubMed ID: 21856683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.